Our goals here are to determine whether BRCA1 is recruited to sites of DNA damage in response to protons in breast cancer cells, to elucidate whether mutation of BRCA1 increases the sensitivity of breast cancer cells to protons, as a basis for personalized medicine, and to explore the effectiveness of combining protons and PARP inhibitors (PARPi). This evidence concerns the gene BRCA1 and breast cancer.